Biotech News

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Emergent BioSolutions (EBS)Emergent BioSolutionsPartnership

Emergent’s Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at

Related news

Emergent BioSolutions

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.

Recent company news

Stock data

Close
5.08 USD
Market cap
423.61M USD
Exchange
NYSE
Sector
Biopharma
Location
United States